WoodsNF, MitchellES, CoslovN, et al.Transitioning to the menopausal transition: a scoping review of research on the late reproductive stage in reproductive aging. Menopause, 2021; 28:447–466.
2.
CrayLA, WoodsNF, HertingJR, et al.Symptom clusters during the late reproductive stage through the early postmenopause: Observations from the Seattle Midlife Women's Health Study. Menopause, 2012; 19:864–869.
3.
HarlowSD, GassM, HallJE, et al.Executive summary of the Stages of Reproductive Aging Workshop +10: Addressing the unfinished agenda of staging reproductive aging. Menopause, 2012; 19:387–395.
4.
Bertone-JohnsonER, MansonJE, Purdue-SmitheAC, et al.Anti-Mullerian hormone levels and incidence of early natural menopause in a prospective study. Hum Reprod, 2018; 33:1175–1182.
5.
GottliebS. “Statement from the FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures of “vaginal rejuveation””. United States Foos and DRug Administration. July 30, 2018. Available at: https://www.fda.cov/new-events/press-announcements/statement-fda-commisioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims (Accessed June6, 2022).
6.
CruzVL, SteinerML, PompeiLM, et al.Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause, 2018; 25:21–28.
7.
ParaisoMFR, FerrandoCA, SokolER, et al.A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause, 2020; 27:50–56.
8.
HolcombD, FaucherMA, BouzidJ, et al.Patient perspectives on audio-only virtual prenatal visits amidst the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pandemic. Obstet Gynecol, 2020; 136:317–322.
